Biotinylated SARS-CoV-2 Spike RBD Beta Variant

CAT:
952-B2010503
Size:
25 µg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Biotinylated SARS-CoV-2 Spike RBD Beta Variant - image 1

Biotinylated SARS-CoV-2 Spike RBD Beta Variant

  • Description:

    Biotinylated SARS-CoV-2 Spike RBD Beta Variant _x000D_ Catalog number: B2010503_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 25 ug_x000D_ Molecular Weight or Concentration: 27 kDa_x000D_ Supplied as: Liquid Solution_x000D_ Applications: molecular component of many serological and antigenic assays for SARS-CoV-2 and its variants_x000D_ Storage: -20℃_x000D_ Keywords: Beta Variant Spike, B.1.351 Spike RBD, Beta RBD, Biotin Beta RBD_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ Download SARS-CoV-2 Brochure_x000D_ _x000D_ References:_x000D_ 1: Aleem A, Akbar Samad AB, Slenker AK. Emerging Variants of SARS-CoV-2 And_x000D_ Novel Therapeutics Against Coronavirus (COVID-19). 2021 Jul 18. In: StatPearls_x000D_ [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–._x000D_ _x000D_ 2: Binette V, Côté S, Haddad M, Nguyen PT, Bélanger S, Bourgault S, Ramassamy C,_x000D_ Gaudreault R, Mousseau N. Corilagin and 1,3,6-Tri-O-galloy-β-D-glucose:_x000D_ potential inhibitors of SARS-CoV-2 variants. Phys Chem Chem Phys. 2021 Jul_x000D_ 14;23(27):14873-14888._x000D_ _x000D_ 3: Kim Y, Gaudreault NN, Meekins DA, Perera KD, Bold D, Trujillo JD, Morozov I,_x000D_ McDowell CD, Chang KO, Richt JA. Effects of Spike Mutations in SARS-CoV-2_x000D_ Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and_x000D_ Neutralization. bioRxiv [Preprint]. 2021 Aug 25:2021.08.25.457627._x000D_ _x000D_ 4: Jin D, Wei J, Sun J. Analysis of the molecular mechanism of SARS-CoV-2_x000D_ antibodies. Biochem Biophys Res Commun. 2021 Aug 20;566:45-52._x000D_ _x000D_ 5: Jette CA, Cohen AA, Gnanapragasam PNP, Muecksch F, Lee YE, Huey-Tubman KE,_x000D_ Schmidt F, Hatziioannou T, Bieniasz PD, Nussenzweig MC, West AP, Keeffe JR,_x000D_ Bjorkman PJ, Barnes CO. Broad cross-reactivity across sarbecoviruses exhibited_x000D_ by a subset of COVID-19 donor-derived neutralizing antibodies. bioRxiv_x000D_ [Preprint]. 2021 Apr 26:2021.04.23.441195._x000D_ _x000D_ 6: Malladi SK, Patel UR, Rajmani RS, Singh R, Pandey S, Kumar S, Khaleeq S, van_x000D_ Vuren PJ, Riddell S, Goldie S, Gayathri S, Chakraborty D, Kalita P, Pramanick I,_x000D_ Agarwal N, Reddy P, Girish N, Upadhyaya A, Khan MS, Kanjo K, Bhat M, Mani S,_x000D_ Bhattacharyya S, Siddiqui S, Tyagi A, Jha S, Pandey R, Tripathi S, Dutta S,_x000D_ McAuley AJ, Singanallur NB, Vasan SS, Ringe RP, Varadarajan R. Immunogenicity_x000D_ and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor_x000D_ Binding Domain Derivative. ACS Infect Dis. 2021 Aug 13;7(8):2546-2564._x000D_ _x000D_ 7: Chen L, Zody MC, Di Germanio C, Martinelli R, Mediavilla JR, Cunningham MH,_x000D_ Composto K, Chow KF, Kordalewska M, Corvelo A, Oschwald DM, Fennessey S,_x000D_ Zetkulic M, Dar S, Kramer Y, Mathema B, Germer S, Stone M, Simmons G, Busch MP,_x000D_ Maniatis T, Perlin DS, Kreiswirth BN. Emergence of Multiple SARS-CoV-2 Antibody_x000D_ Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma_x000D_ Treatment. mSphere. 2021 Aug 25;6(4):e0048021._x000D_ _x000D_ 8: Tian F, Tong B, Sun L, Shi S, Zheng B, Wang Z, Dong X, Zheng P. N501Y_x000D_ mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor_x000D_ ACE2. Elife. 2021 Aug 20;10:e69091._x000D_ _x000D_ 9: Makdasi E, Zvi A, Alcalay R, Noy-Porat T, Peretz E, Mechaly A, Levy Y,_x000D_ Epstein E, Chitlaru T, Tennenhouse A, Aftalion M, Gur D, Paran N, Tamir H,_x000D_ Zimhony O, Weiss S, Mandelboim M, Mendelson E, Zuckerman N, Nemet I, Kliker L,_x000D_ Yitzhaki S, Shapira SC, Israely T, Fleishman SJ, Mazor O, Rosenfeld R. The_x000D_ neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal_x000D_ antibodies is retained against viral variants. Cell Rep. 2021 Aug 21:109679._x000D_ 10: Lee YG, Kang KW, Hong W, Kim YH, Oh JT, Park DW, Ko M, Bai YF, Seo YJ, Lee_x000D_ SM, Kim H, Kang SC. Potent antiviral activity of Agrimonia pilosa, Galla rhois,_x000D_ and their components against SARS-CoV-2. Bioorg Med Chem. 2021 Sep 1;45:116329._x000D_ _x000D_ Products Related to Biotinylated SARS-CoV-2 Spike RBD Beta Variant : SARS-CoV-2
  • Short Description:

    Catalog Number: B2010503 (25 ug)
  • Weight:

    0.15
  • Length:

    2
  • Width:

    0.5
  • Height:

    0.5
  • Height :

    0.5